US President Donald Trump has listed India, Pakistan, Afghanistan, Burma and China among 23 nations identified as "major drug transit or major illicit drug producing" countries. In a Presidential Determination submitted to Congress, Trump warned that these countries, by producing or enabling the movement of illegal narcotics and precursor chemicals, posed a threat to the safety of the US and its citizens.&nbsp;The list of all 23 countries includes Afghanistan, The Bahamas, Burma, China, Belize, Bolivia, Colombia, Costa Rica, the Dominican Republic, Ecuador, El Salvador, India, Guatemala, Haiti, Honduras, Jamaica, Laos, Mexico, Nicaragua, Pakistan, Panama, Peru and Venezuela.&nbsp;The White House explained that the "Major’s List" flags those countries that serve as key sources or transit points for drugs entering the US. The State Department noted that the designation applies not only to producers but also to nations used as trafficking routes.&nbsp;Five countries, Afghanistan, Bolivia, Burma, Colombia and Venezuela, were further criticised for "failing demonstrably" to make significant efforts to combat narcotics production and trafficking, according to a report in Indian Today.<h3>Geographic and economic conditions make drug production possible</h3>The US State Department pointed out that geographic and economic conditions make drug production or transit possible, and inclusion on the list does not necessarily represent a lack of cooperation by governments. "The listing is based on the combination of geographic, commercial, and economic factors that allow drugs or precursor chemicals to be transited or produced, even if a government has engaged in robust and diligent narcotics control and law enforcement measures," the statement said.&nbsp;Donald Trump hit out at China, labelling it the "world’s largest source" of precursor chemicals used in fentanyl production. "The country’s role as the world's largest source of precursor chemicals fuelling illicit fentanyl production has been well documented," Trump said in a statement.&nbsp;&nbsp;

The list of all 23 countries includes Afghanistan, The Bahamas, Burma, China, Belize, Bolivia, Colombia, Costa Rica, the Dominican Republic, Ecuador, El Salvador, India, Guatemala, Haiti, Honduras, Jamaica, Laos, Mexico, Nicaragua, Pakistan, Panama, Peru and Venezuela.

US President Donald Trump has listed India, Pakistan, Afghanistan, Burma and China among 23 nations identified as "major drug transit or major illicit drug producing" countries. In a Presidential Determination submitted to Congress, Trump warned that these countries, by producing or enabling the movement of illegal narcotics and precursor chemicals, posed a threat to the safety of the US and its citizens. The list of all 23 countries includes Afghanistan, The Bahamas, Burma, China, Belize, Bolivia, Colombia, Costa Rica, the Dominican Republic, Ecuador, El Salvador, India, Guatemala, Haiti, Honduras, Jamaica, Laos, Mexico, Nicaragua, Pakistan, Panama, Peru and Venezuela. The White House explained that the "Major’s List" flags those countries that serve as key sources or transit points for drugs entering the US. The State Department noted that the designation applies not only to producers but also to nations used as trafficking routes. Five countries, Afghanistan, Bolivia, Burma, Colombia and Venezuela, were further criticised for "failing demonstrably" to make significant efforts to combat narcotics production and trafficking, according to a report in Indian Today. Geographic and economic conditions make drug production possible The US State Department pointed out that geographic and economic conditions make drug production or transit possible, and inclusion on the list does not necessarily represent a lack of cooperation by governments. "The listing is based on the combination of geographic, commercial, and economic factors that allow drugs or precursor chemicals to be transited or produced, even if a government has engaged in robust and diligent narcotics control and law enforcement measures," the statement said. Donald Trump hit out at China, labelling it the "world’s largest source" of precursor chemicals used in fentanyl production. "The country’s role as the world's largest source of precursor chemicals fuelling illicit fentanyl production has been well documented," Trump said in a statement.

The list of all 23 countries includes Afghanistan, The Bahamas, Burma, China, Belize, Bolivia, Colombia, Costa Rica, the Dominican Republic, Ecuador, El Salvador, India, Guatemala, Haiti, Honduras, Jamaica, Laos, Mexico, Nicaragua, Pakistan, Panama, Peru and Venezuela.

Is India fueling 'global drug' trade? Trump lists India, Pakistan among 23 ‘major drug-producing' nations

Health care ought to be affordable and accessible with this ambitious goal, Iran set up many drug factories. Today it is a world leader in the production of generic drugs.

They have even branched out into making cancer drugs. Middle east's biggest cancer drug producer is in Iran. But over the past two years, drug production has dropped. Vital cancer drugs went off the shelf drug companies attribute this to the US Sanctions.

The import restriction is not on drug salts alone equipment used by the drug companies face sanctions under the label "dual-use".

Procuring spare parts for existing machines has become an uphill task what Iran has lost due to sanctions is immense.

The US exported 26 million dollars worth pharmaceutical products to Iran. Since 2018, this has fallen to over 8 million dollars.&nbsp;

French pharmaceutical exports till 2018 were 218 million dollars after sanctions, they fell by 25 per cent to 164 million dollars.

Exports from Swiss pharma companies were 240 million dollars in 2017 within a year, the business dropped to 167 million dollars.

According to Dr Reza Mostofi, general manage of Actoverco production plant "One of the other products that we are producing is Rituximab which is a monoclonal antibody; Rituximab is used in leukaemia, in breast cancer and many other types of cancer, that's the main immunotherapy drug for the patients. So for some times, we haven't been able to import the ingredients of this material so our line for Rituximab is now stopped."

"In radiotherapy or nuclear medicine, these sanctions have had an impact. We are producers of nuclear medicine ourselves, but again, some aspects of them have been sanctioned under the pretence of multiple functions," said Kianoosh Jahanpoor, Iran Health Ministry Spokesman.

Sanctions impact on Iran

The United States of America 
$ 26 million: US pharma exports till 2018 
$ 8.6 million: US pharma exports in 2018-19

France&nbsp; 
Pre-sanction: $ 218 million pharma exports&nbsp; 
Post-sanction: $ 164 million (drop of 25%)

Switzerland 
Pharma exports in 2017: $ 240 million in 2017 
Pharma exports in 2018: $ 167 million in 2018

Health care ought to be affordable and accessible with this ambitious goal, Iran set up many drug factories. Today it is a world leader in the production of generic drugs.

Health care ought to be affordable and accessible with this ambitious goal, Iran set up many drug factories. Today it is a world leader in the production of generic drugs. They have even branched out into making cancer drugs. Middle east's biggest cancer drug producer is in Iran. But over the past two years, drug production has dropped. Vital cancer drugs went off the shelf drug companies attribute this to the US Sanctions. The import restriction is not on drug salts alone equipment used by the drug companies face sanctions under the label "dual-use". Procuring spare parts for existing machines has become an uphill task what Iran has lost due to sanctions is immense. The US exported 26 million dollars worth pharmaceutical products to Iran. Since 2018, this has fallen to over 8 million dollars. French pharmaceutical exports till 2018 were 218 million dollars after sanctions, they fell by 25 per cent to 164 million dollars. Exports from Swiss pharma companies were 240 million dollars in 2017 within a year, the business dropped to 167 million dollars. According to Dr Reza Mostofi, general manage of Actoverco production plant "One of the other products that we are producing is Rituximab which is a monoclonal antibody; Rituximab is used in leukaemia, in breast cancer and many other types of cancer, that's the main immunotherapy drug for the patients. So for some times, we haven't been able to import the ingredients of this material so our line for Rituximab is now stopped." "In radiotherapy or nuclear medicine, these sanctions have had an impact. We are producers of nuclear medicine ourselves, but again, some aspects of them have been sanctioned under the pretence of multiple functions," said Kianoosh Jahanpoor, Iran Health Ministry Spokesman. Sanctions impact on Iran The United States of America $ 26 million: US pharma exports till 2018 $ 8.6 million: US pharma exports in 2018-19 France Pre-sanction: $ 218 million pharma exports Post-sanction: $ 164 million (drop of 25%) Switzerland Pharma exports in 2017: $ 240 million in 2017 Pharma exports in 2018: $ 167 million in 2018

US sanctions cut off Iranians' access to medicine

drug-production

Drug Production, News on Drug Production, stories on Drug Production, articles on Drug Production, Drug Production stories at Wion, Drug Production news, Drug Production latest news